Project description
Improving immune-oncology treatments efficacy
Immunotherapy offers hope in the fight against cancer, but with a response rate of only 10-20 % in solid tumours, its potential remains underutilised. Predicting patient responses to this treatment is an urgent medical need that current methods inadequately address. The EIC-funded Improving IO (IOO) project will develop a validated multiplexed biomarker assay based on proprietary bio-imaging technology. Although scientifically validated, it requires further clinical validation for regulatory certification. This assay could significantly improve the efficacy of immune-oncology treatments by accurately predicting patient responses to immune checkpoint inhibitors, which underpin 90 % of current therapies. If successful, it could be adopted in hospitals worldwide, potentially doubling survival rates for lethal tumours such as lung cancer.
Objective
Immunotherapy is a beacon of hope in cancer's battle, but with a 10-20% response rate in solid tumors, its potential is untapped. Predicting patient responses to treatment, which current methods are ill-equipped for, is an urgent unmet medical need. Our project stands for industrializing our analytically validated multiplexed protein-function based biomarker assay (IOO), currently TRL6, which is based on our proprietary bio-imaging technology. Whilst scientifically validated, we need further clinical validation to obtain increased datasets required for regulatory certification for clinical deployment. This assay could triple the efficacy of currently available immune-oncology treatments by accurately predicting patient response to immune checkpoint inhibitors - the basis of 90% of current immuno-oncology therapies. If successful, we will bring this transformative solution to hospitals worldwide. The upshot could be game-changing: doubling survival rates for high-prevalence, lethal tumors like lung cancer.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
48160 DERIO BIZKAIA
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.